近日,湖南省肿瘤医院杨农教授和张永昌教授团队在Cancer Immunology, Immunotherapy(IF 5.442)杂志上发表了一篇PD-1抑制剂联合安罗替尼在晚期肺癌患者应用的真实世界研究《Anlotinib combined with PD-1 blockade for thetreatment of…阅读全文 赞同 添加评论 分享收藏 ...
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71. [Crossref] [PubMed] Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immu...
[5]Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4. [6]Zhu Y, Chen M, Xu D, et al...
in vivo blocking of PD-1/PD-L signaling Evans, E. E., et al. (2015). "Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies" Cancer Immunol Res 3(6): 689-701.in vivo blocking of PD-1/PD-L signaling Zelenay,...
Molecular classification of endometrial cancer and its association with PD-1/PD-L1 blockade 在线阅读 下载PDF 引用 收藏 分享 摘要 子宫内膜癌是女性生殖道三大恶性肿瘤之一。癌症基因图谱计划根据子宫内膜癌的分子特征提出了POLE(DNA polymeraseε,POLE)突变型;微卫星不稳定高突变型;拷贝数低型和拷贝数高型/...
Evans, E. E., et al. (2015). "Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies" Cancer Immunol Res 3(6): 689-701. in vivo blocking of PD-1/PD-L signaling ...
Cancerimmunology.MutationallandscapedeterminessensitivitytoPD-1blockadeinnon-smallcelllungcancer. 2016年,权威的学术期刊《Science》发表了纽约长老会和哥伦比亚大学的研究成果(Rizvietal.,2015):研究者对34位使用PD-1抗体的非小细胞肺癌患者进行全外显子基因测序,也发现基因突变数多的患者更容易从PD-1抗体治疗中获益。
近日,中山大学附属第六医院邓艳红团队在国际知名期刊Cancer Cell上发表了最新研究成果“Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer”。首次对接受PD-1阻断剂与COX-2抑制剂治疗的d-MMR / MSI-H CRC患者的细胞群进行了深入的细胞和分子...
Cancerimmunology.MutationallandscapedeterminessensitivitytoPD-1blockadeinnon-smallcelllungcancer. 2016年,权威的学术期刊《Science》发表了纽约长老会和哥伦比亚大学的研究成果(Rizvietal.,2015):研究者对34位使用PD-1抗体的非小细胞肺癌患者进行全外显子基因测序,也发现基因突变数多的患者更容易从PD-1抗体治疗中获益。
4.Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.Sandin LC;Totterman TH;Anger K;Mangsbo SM;Loskog A;Korman AJ-Journal of immunotherapy-2010第3期 5.Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.S E ...